Last reviewed · How we verify
oxaliplatin and gemcitabine
Oxaliplatin works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, leading to cell death. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by causing DNA strand breaks.
Oxaliplatin works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, leading to cell death. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by causing DNA strand breaks. Used for Advanced pancreatic cancer, Advanced colorectal cancer.
At a glance
| Generic name | oxaliplatin and gemcitabine |
|---|---|
| Also known as | oxaliplatin, gemcitabine |
| Sponsor | Shanghai Zhongshan Hospital |
| Drug class | Platinum-based chemotherapeutic agent and nucleoside analog |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Oxaliplatin is a platinum-based chemotherapeutic agent that forms platinum-DNA adducts, which interfere with DNA replication and transcription, leading to cell death. This results in the inhibition of cancer cell growth and induction of apoptosis. Gemcitabine, on the other hand, is a nucleoside analog that is incorporated into DNA during replication, causing DNA strand breaks and inhibiting DNA synthesis.
Approved indications
- Advanced pancreatic cancer
- Advanced colorectal cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Anemia
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
- Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxaliplatin and gemcitabine CI brief — competitive landscape report
- oxaliplatin and gemcitabine updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI